Cover Image
市場調查報告書

末梢性T細胞淋巴瘤 (PTCL):開發中產品分析

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 264096
出版日期 內容資訊 英文 246 Pages
訂單完成後即時交付
價格
Back to Top
末梢性T細胞淋巴瘤 (PTCL):開發中產品分析 Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 246 Pages
簡介

末梢性T細胞淋巴瘤 (PTCL) 是被稱為T淋巴球的白血球(T細胞)所產生,罕見具侵略性(急速成長)的癌症。T細胞是免疫系統的重要要素,有助於身體對抗傳染病。一旦T細胞急速成長,開始瀕死抵抗,就會在體內積存。可見的症狀有倦怠感、頭·腋下·鼠蹊部無痛腫起,盜汗、皮疹等。

本報告提供末梢性T細胞淋巴瘤 (PTCL) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

末梢性T細胞淋巴瘤 (PTCL)的概要

治療藥的開發

  • 開發中產品的概要

末梢性T細胞淋巴瘤 (PTCL):企業開發中的治療藥

末梢性T細胞淋巴瘤 (PTCL):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

末梢性T細胞淋巴瘤 (PTCL):企業開發中的產品

末梢性T細胞淋巴瘤 (PTCL)的治療藥開發企業

  • AB Science SA
  • Affimed GmbH
  • arGEN-X BV
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • CerRx, Inc.
  • Chipscreen Biosciences Ltd
  • CSPC Pharmaceutical Group Limited
  • Eisai
  • Genosco
  • Incyte Corporation
  • 日本煙草產業
  • Johnson & Johnson
  • Mundipharma International Ltd
  • 小野藥品工業
  • Onxeo SA
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Portola Pharmaceuticals, Inc.
  • Rhizen Pharmaceuticals S.A.
  • Seattle Genetics, Inc.
  • Solasia Pharma K.K.
  • Spectrum Pharmaceuticals, Inc.

末梢性T細胞淋巴瘤 (PTCL):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

末梢性T細胞淋巴瘤 (PTCL):暫停中的計劃

末梢性T細胞淋巴瘤 (PTCL):開發中止的產品

末梢性T細胞淋巴瘤 (PTCL):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8436IDB

Summary

Global Markets Direct's, 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016', provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
  • The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects
  • The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peripheral T-Cell Lymphomas (PTCL) Overview
  • Therapeutics Development
    • Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview
  • Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies
  • Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development
    • AB Science SA
    • Affimed GmbH
    • arGEN-X BV
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Celgene Corporation
    • CerRx, Inc.
    • Chipscreen Biosciences Ltd
    • CSPC Pharmaceutical Group Limited
    • Eisai Co., Ltd.
    • Genosco
    • Incyte Corporation
    • Japan Tobacco Inc.
    • Johnson & Johnson
    • Mundipharma International Ltd
    • Ono Pharmaceutical Co., Ltd.
    • Onxeo SA
    • Pfizer Inc.
    • Pharma Mar, S.A.
    • Portola Pharmaceuticals, Inc.
    • Rhizen Pharmaceuticals S.A.
    • Seattle Genetics, Inc.
    • Solasia Pharma K.K.
    • Spectrum Pharmaceuticals, Inc.
  • Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AFM-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARGX-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brentuximab vedotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD7 for Relapsed and Refractory Leukemia and Lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerdulatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • copanlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darinaparsin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denileukin diftitox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enasidenib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fenretinide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • forodesine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICG-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-570 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mitoxantrone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NL-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plitidepsin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pralatrexate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romidepsin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-6530 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ruxolitinib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SH-7129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • temsirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TGR-1202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tipifarnib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tucidinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • volasertib trihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects
  • Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products
  • Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 16, 2016: CAR T-cells Targeting the CD4 Protein Granted FDA Orphan Drug Designation
      • Aug 11, 2016: CAR T-cells Targeting the CD4 Protein Granted Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma
      • Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma
      • Jun 02, 2016: Onxeo Announces Development of Beleodaq Oral Formulation Opening New Opportunities for Its HDAC Inhibitor
      • Mar 28, 2016: Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma
      • Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
      • Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015
      • Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP
      • Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma
      • Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
      • Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology
      • May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3
      • Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China
      • Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
      • Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed GmbH , H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by arGEN-X BV, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Genosco, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Japan Tobacco Inc., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pharma Mar, S.A., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H2 2016
  • Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top